Top Pharmaceutical Companies by Annual Revenue 2025

About This Dataset

Pharmaceutical and healthcare companies ranked by total annual revenue in billions of USD in 2025, according to company earnings reports and EvaluatePharma data. Johnson and Johnson leads global pharmaceutical revenue rankings in 2025 — maintaining its position through a diversified portfolio that spans oncology, immunology, and neuroscience following its separation of the consumer health business into Kenvue in 2023, which allowed the remaining pharmaceutical and MedTech operations to focus entirely on high-margin prescription drugs and medical devices. Merck and AbbVie trail closely, with Merck's Keytruda cancer immunotherapy generating over $25 billion in annual sales alone.

Analysis

Johnson & Johnson heads the table on 88, ahead of Merck & Co. (68) and Roche (62) in Annual Revenue (Billion USD) in 2025. The total is spread widely: even Johnson & Johnson accounts for only 18.4% of the 8 combined. Places 3 to 8 are close together, spanning 62 to 48.

Source: Wikipedia

Key Findings

🏆

Johnson & Johnson leads in Annual Revenue (Billion USD) with 88 in 2025.

📊

Average Annual Revenue (Billion USD) in 2025: 60 · median: 56.

↔️

Gap in 2025: Johnson & Johnson is 1.8× larger than Bristol-Myers Squibb.

Top Pharmaceutical Companies by Annual Revenue 2025

Bar

H-Bar

Line

Area

🗺 Map

Table

Data Insights Below

Data Insights

Numbers, trends & sources behind this chart

Admin

⬡

Data Points

8 categories · 1 year

↑

Top Value

Johnson & Johnson

Annual Revenue (Billion USD) · 2025

◈

Metrics

Annual Revenue (Billion USD)

◷

Period

2025

Single year snapshot

Methodology & source

Data source: Wikipedia
Coverage: 8 entities · 2025 · 8 observations
Measure: Annual Revenue (Billion USD)
Last updated: 6 September 2026
Compiled by: The ANYSTAT team, from the source above

How the figures are calculated

Values are shown as reported by the source. Nothing is rescaled, rebased or converted — the only changes are thousand separators and decimals shown to two places.
Entities are ranked highest-first on their value in 2025.